Skip to main content
. Author manuscript; available in PMC: 2014 Feb 1.
Published in final edited form as: Biol Blood Marrow Transplant. 2012 Oct 13;19(2):260–265. doi: 10.1016/j.bbmt.2012.09.023

Figure 1. Cumulative incidence of second malignancy in the cohort.

Figure 1

Cumulative incidence of second malignancy (%) from date of ASCT (years) was calculated using death from other causes as a competing risk. N at risk was 841 at ASCT (time 0), 378 at 5 years and 82 at 10 years. The solid black line represents overall cumulative incidence (all types of SPM), the grey line represents overall cumulative incidence (SPM excluding non-myeloma skin cancers), the dashed line represents solid tumors (SPM excluding non-myeloma skin cancers), and the dotted line represents t-MDS/AML.